-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 25th, Hengrui Pharmaceuticals announced that the company has recently received a "Drug Clinical Trial Approval Notice" for SHR7280 tablets issued by the State Food and Drug Administration, and clinical trials will be launched in the near future
SHR7280 is an oral small molecule GnRH receptor antagonist, which can block the binding of endogenous GnRH and GnRH receptor, inhibit the synthesis and release of luteinizing hormone and follicle stimulating hormone and other gonadotropins, and reduce testosterone and estradiol And other sex hormone levels
Up to now, SHR7280 related research and development projects have invested a total of approximately RMB 50.